Boston Scientific Stock: Discounted and Worth a Second Look
2 extracted signals · 0 resolved · 2 still active
Victor H InvestingIndependent analyst profile- Source published
- 24 Jul 2026, 16:00 UTC
- Recorded by Tahlil Plus
- 02 Sept 2026, 08:44 UTC
AI-generated source summary
The analysis focuses on Boston Scientific (BSX) and ResMed (RMD), both medical device companies. BSX is currently trading at $44.77, with a price target of $57, implying a potential upside of approximately 27%. The stock has seen recent price pressure, dropping from a high around $60 to its current level, but fundamental data such as revenue growth and free cash flow indicate a strong underlying business. The P/E ratio of 32 and a 35% discount on intrinsic value suggest it's undervalued. The analyst consensus is a 'Strong Buy'. The target price of $57 suggests a bullish outlook, with a fail bound set at $35, below which the bullish thesis would be invalidated. For RMD, the current price is $205.87, with a target of $300. The analysis indicates a significant discount of 51% compared to its intrinsic value, with strong historical performance in revenue and free cash flow growth. A bullish trend is predicted for RMD, with a fail bound at $150. Both stocks are in the healthcare sector, which is considered defensive and has consistent demand for its products.
AI-generated summary based on the source content.
Signal outcomes at a glance
Tracking LiveSignals in this source
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
2 eligible signals linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- Source processing completed
Source analysis and structured extraction completed.
- Live evaluation in progress
2 signals remain active.
Victor H Investing
Platform-wide history, separate from this source evaluation.
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.